Estrogen Patch Shortages in Canada
The Canadian Pharmacists Association (CPhA) lists menopausal hormone therapy among active Canadian supply challenges, specifically naming estrogen patches and Premarin vaginal cream, while noting that alternative products remain available. The federal shortage registry names the individual products affected.
What CPhA is reporting
According to CPhA's active shortages page, as of September 2026 there were supply challenges affecting some estrogen products in Canada, including patches and Premarin vaginal cream, with Health Canada in contact with manufacturers and monitoring the supply situation. CPhA attributes the intermittent shortages to increased demand for menopausal hormone therapy products combined with manufacturer disruptions.
CPhA has published a clinical resource dated March 13, 2026 to support pharmacists helping patients navigate the shortage and available alternatives. The association also notes that at any given time, there are between 1,500 and 2,000 active drug shortages in Canada.
What the shortage registry lists
Health Product Shortages Canada, the federal registry where manufacturers report shortages, listed three active estradiol shortages as of August 24, 2026:
- Lupin-Estradiol 2 mg tablets, reported August 9, 2026
- Estalis 140/50 mcg patch, reported July 16, 2026
- Estradot 100 mcg patch, reported July 16, 2026
Earlier 2026 shortages of Lupin-Estradiol 0.5 mg and 1 mg tablets and of the Estradot 25 and 75 patches were marked resolved, with resolution dates in May and June 2026. The registry also lists four estradiol discontinuations: the Oesclim 50 mcg and 25 mcg patches (August 6 and July 31, 2024) and the Climara Pro and Climara 100 patches (November 2017).
Over its full history, the registry's estradiol page showed 121 shortage reports and four discontinuation reports as of late August 2026. CBC, citing the Drug Shortages Canada database, counted 92 shortages and four discontinuations of estradiol-containing products since 2017, across transdermal patches, pills, vaginal rings, topical gels and creams.
Why hormone supply chains break
The raw-materials picture behind menopausal hormone therapy helps explain why shortages recur. The starting ingredient for semi-synthesis of estradiol and progesterone is stigmasterol, derived from soybeans, with soybean supply for hormone production concentrated in China and India. The same two countries dominate the world market in converting stigmasterol into hormone active pharmaceutical ingredients (APIs), with Israel and the Netherlands also producing hormone APIs at large scale.
About 94% of APIs that eventually become medications in the United States come from China or India, according to the vajenda analysis. When most companies rely on two countries for an API, a single environmental or factory-related issue can trigger a worldwide supply gap. The same stigmasterol feedstock is also used to manufacture hormones for birth control pills, patches, rings, hormone IUDs and testosterone, meaning API producers may prioritize the products with the better profit margin.
US data cited in the analysis show that when a hormone shortage occurs, it typically lasts approximately 1,201 days. As of February 13, 2026, 194 drugs were reported as impacted by shortages in the United States.
Lead times are long once supply does tighten. Christian Ouellet, vice-president of corporate affairs at Sandoz Canada, told CBC that producing a drug can take 18 to 24 months, from sourcing raw materials to distribution.
Demand from the United States
CBS News reported that US prescriptions for estradiol patches rose from about 594,000 in June 2024 to 1.6 million in May 2026, and that a group of Democratic members of the US House of Representatives urged the FDA to add the patches to its federal drug shortage database. In its September update, the FDA said that although availability of certain products or brands varies by pharmacy or location, estradiol transdermal patches remain available.
Health Canada's shortage framework
Health Canada defines a drug shortage as any situation in which a manufacturer cannot supply enough of a drug to meet all Canadian orders on time, and requires manufacturers of certain drugs to report anticipated and actual shortages on the drug shortage reporting website. When a shortage has the potential to pose a significant risk, the Health Product Shortages Directorate assembles a Tier Assignment Committee, with Tier 3 representing the most serious level.
Available federal mitigation tools include using regulatory powers to allow drugs labelled and approved for other markets to be imported into Canada, fast-tracking regulatory reviews, and extending the shelf life of a drug when suitable supporting data exist. The CPhA notice does not indicate that menopausal hormone therapy has been assigned Tier 3 status.
British Columbia
Global News reported that B.C. health officials confirmed a shortage of estrogen patches in the province, arriving alongside the PharmaCare change that made menopausal hormone therapy fully covered for MSP-enrolled residents from March 1, 2026. Which patch strengths B.C. covers in full, and which only as a partial benefit, is set out in our Plan NP product list and on the British Columbia coverage page.
Prices and coverage
WomensHealthPrices.ca tracks pharmacy and telehealth prices for vaginal estrogen, estradiol patches and Premarin. The coverage tracker shows whether each provincial plan covers hormone therapy, and the online menopause treatment page compares what online providers charge.
Key facts
- Products flagged by CPhA: estrogen patches and Premarin vaginal cream
- Alternative products: remain available per CPhA
- CPhA clinical resource: March 13, 2026
- Active estradiol listings, August 24, 2026: Lupin-Estradiol 2 mg, Estalis 140/50, Estradot 100
- Tier 3 designation: none indicated
- API sourcing: hormone APIs concentrated in China and India
Updated October 28, 2026: this article now includes the registry, US and B.C. reporting from earlier WomensHealthPrices.ca articles on the same shortage, which redirect here. Each figure is dated to when its source reported it.
This article is for informational purposes only and does not constitute medical advice.
Sources
- Managing current drug shortages - English
- Reports for ESTRADIOL
- Worldwide shortages of hormone replacement medication ...
- Why is there a Shortage of Menopause Hormone Therapy?
- Estrogen patch shortage prompts doctors, lawmakers to ...
- Shortage of estrogen patches in B.C. but officials say not to ...
- Drug shortages in Canada
Get notified about price changes
Weβll send an email when prices change at Canadian pharmacies and telehealth providers. No spam.
Track treatment prices at Canadian pharmacies
Get notified when prices change at Canadian pharmacies and telehealth providers.